Nov 20, 2024 7:02am EST Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Sep 26, 2024 6:44pm EDT Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Sep 26, 2024 7:02am EDT Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Sep 09, 2024 8:01am EDT Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Sep 03, 2024 8:02am EDT Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Aug 28, 2024 9:11am EDT Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Jun 13, 2024 6:59am EDT Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
May 28, 2024 6:59am EDT Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
Apr 29, 2024 7:59am EDT Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Apr 24, 2024 7:59am EDT Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
